Shares of Synthorx Inc (NASDAQ:THOR) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $16.64 and traded as high as $18.66. Synthorx shares last traded at $17.83, with a volume of 339 shares.
A number of research analysts recently weighed in on THOR shares. ValuEngine raised Synthorx from a “hold” rating to a “buy” rating in a research note on Thursday, August 15th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Synthorx in a research note on Wednesday, May 1st. Finally, Zacks Investment Research downgraded Synthorx from a “buy” rating to a “hold” rating in a research note on Thursday, August 8th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $22.67.
The business has a 50 day moving average of $15.71 and a two-hundred day moving average of $16.64. The firm has a market capitalization of $553.04 million and a price-to-earnings ratio of -2.71.
A number of institutional investors and hedge funds have recently modified their holdings of THOR. BlackRock Inc. grew its holdings in shares of Synthorx by 25.7% in the second quarter. BlackRock Inc. now owns 543,305 shares of the medical instruments supplier’s stock valued at $7,341,000 after acquiring an additional 111,165 shares in the last quarter. Vanguard Group Inc. grew its holdings in Synthorx by 8.4% during the second quarter. Vanguard Group Inc. now owns 336,963 shares of the medical instruments supplier’s stock valued at $4,552,000 after purchasing an additional 26,085 shares during the period. Morgan Stanley grew its holdings in Synthorx by 9,312.2% during the second quarter. Morgan Stanley now owns 123,112 shares of the medical instruments supplier’s stock valued at $1,663,000 after purchasing an additional 121,804 shares during the period. Emory University bought a new position in Synthorx during the first quarter valued at $2,439,000. Finally, Northern Trust Corp grew its holdings in Synthorx by 1.6% during the second quarter. Northern Trust Corp now owns 92,542 shares of the medical instruments supplier’s stock valued at $1,251,000 after purchasing an additional 1,483 shares during the period. 64.43% of the stock is owned by hedge funds and other institutional investors.
Synthorx Company Profile (NASDAQ:THOR)
Synthorx, Inc, a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor.
Recommended Story: Differences Between Momentum Investing and Long Term Investing
Receive News & Ratings for Synthorx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthorx and related companies with MarketBeat.com's FREE daily email newsletter.